title: Pharmaceutical funding decisions must balance therapeutic innovation, opportunity costs and patient equity.
authors.affiliation: Clinical Trials and Research Pharmacist, Pharmacy Services, Waikato Hospital, Hamilton.
authors.forename: Rajan
authors.initials: R
authors.lastname: Ragupathy
authors.affiliation: Medical Oncologist, Regional Cancer Centre, Waikato Hospital, Hamilton. Associate Professor, Waikato Clinical Campus, Faculty of Medical and Health Sciences, University of Auckland, Hamilton.
authors.forename: Michael
authors.initials: M
authors.lastname: Jameson
mesh_terms: D000970:Antineoplastic Agents / Q000191:economics*; D016527:Drug Costs / Q000639:trends*; D004345:Drug Industry / Q000191:economics*; D005380:Financing, Government / Q000191:economics*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy; D009520:New Zealand
chemical_list: D000970:Antineoplastic Agents